Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631324 | 0.92 | MAP4K1 (0.59) | MAP4K1SMG1CDK1CDK2MTOR | |
| SCHEMBL1632820 | 0.92 | SMG1 (0.58) | MAP4K1CA1CA2CA9SMG1 | |
| SCHEMBL1631045 | 0.89 | SMG1 (0.59) | MAP4K1CA1CA2CA9SMG1 | |
| SCHEMBL1634389 | 0.82 | IKBKB (0.49) | CA1CA2CA9CA4CDK1 | |
| SCHEMBL1632659 | 0.82 | CA1 (0.47) | CA1CA2CA9SMG1CHRNA7 | |
| SCHEMBL1633314 | 0.82 | MAPK10 (0.49) | CA1CA2CA9SMG1CHRNA7 | |
| SCHEMBL1631337 | 0.81 | CA1 (0.48) | CA1CA2CA9CA4CDK1 | |
| SCHEMBL1633026 | 0.81 | SMG1 (0.59) | MAP4K1SMG1JAK2CDK1CDK2 | |
| SCHEMBL1633017 | 0.81 | SMG1 (0.72) | MAP4K1CA1CA2CA9SMG1 | |
| SCHEMBL1633466 | 0.81 | CA1 (0.48) | MAP4K1CA1CA2CA9CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAP4K1 48/4885CA1 4702/4885CA2 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.